Viking Therapeutics reported first-quarter 2026 financial results yesterday afternoon, and the headline numbers tell the story of a clinical-stage biotech burning cash to enroll the largest obesity-drug Phase 3 program currently in flight. Net loss of $158.3 million ($1.37 per share) compared with $45.6 million a year earlier. Research and development spending jumped to $150.2 million from $41.4 million. Cash and short-term investments at $603 million, down from $706 million at year-end. The market dropped the stock 8.5% on the report. (Viking Therapeutics Q1 2026 release)

Three pipeline updates from the call are more consequential than the financial print, and one of them changes the competitive landscape going forward.

VANQUISH Is Fully Enrolled

The Phase 3 VANQUISH program for subcutaneous VK2735, Viking’s GLP-1/GIP dual agonist, is now completely enrolled. VANQUISH-1 finished with more than 4,500 patients—exceeding the original target—and VANQUISH-2 closed at approximately 1,000 patients. Combined, this is the largest fully enrolled Phase 3 obesity-drug pivotal program currently active.

Topline results from VANQUISH are not imminent—the trials are 78 weeks of treatment plus follow-up, with primary readouts expected in 2027 and 2028. But “fully enrolled” eliminates the single largest execution risk for a Phase 3 program. The remaining risk is whether the drug works in humans the way it did in Phase 2, where the subcutaneous formulation produced 14.7% weight loss at 13 weeks—a result that, if it holds at 78 weeks, would put VK2735 in the same competitive band as tirzepatide.

Oral VK2735 Slips a Quarter

The Phase 3 trial of oral VK2735 in obesity has been pushed to Q4 2026, from the previously guided Q3 start. A maintenance dosing study, evaluating whether patients on VK2735 can sustain weight loss with reduced-frequency dosing, remains on track for Q3 2026 topline.

A one-quarter delay on a development-stage program is not necessarily meaningful in itself. What matters is the context. Oral GLP-1 is the newly contested ground in obesity pharmacology: Eli Lilly’s Foundayo (orforglipron) was approved April 1 and is shipping; Novo Nordisk’s oral semaglutide (Wegovy pill) is running approximately 50,000 weekly prescriptions in the United States. If Viking’s oral VK2735 can hit a competitive efficacy profile, it will enter a category that’s already moving without it. The Q4 start versus Q3 start matters less than the cumulative time-to-market gap.

VK3019 Is the Pipeline Surprise

The most strategically interesting item in the call is the program Viking hasn’t yet talked about much. Its lead amylin agonist, VK3019, completed an IND filing in Q1 and is targeted for a Phase 1 SAD/MAD study starting in Q2 2026.

Viking’s framing is significant. Management noted that dual activation of the amylin and calcitonin receptors “could represent an attractive treatment option for patients who are not candidates for GLP-1 therapeutics due to tolerability or other reasons.” That’s a clear positioning play. The amylin agonist class—being independently developed by Pfizer (PF-3944), Alveus Therapeutics (ALV-200), and others—is staking a claim on the substantial fraction of the obesity-treatment population that cannot tolerate GLP-1 mechanisms or has not responded to them.

The detail that turned heads on the call: VK3019 produced superior weight loss to VK2735 in primate preclinical data. That’s a strong signal in the most translationally predictive nonhuman model commonly used for metabolic drug development. It does not guarantee comparable performance in humans, but it places VK3019 in a different category than the typical “early Phase 1” candidate—the company is essentially telling the market it has a backup molecule that may outperform its lead.

What This Says About the Pipeline

Three things are now visible in Viking’s positioning that weren’t a quarter ago.

First, the financial commitment is real. R&D spending tripled year-over-year. The company is not coasting on Phase 2 data or preserving cash for a potential acquisition; it’s running multiple Phase 3 trials and a Phase 1 in parallel, on a $600M cash position. That’s a ~24-month runway at current burn—enough to reach VANQUISH topline, but not by much.

Second, Viking is hedging mechanism risk. By advancing both a GLP-1/GIP dual agonist and an amylin agonist with no GLP-1 activity, the company is positioning to compete in two distinct mechanism categories. If the GLP-1 dogma holds, VK2735 is its play. If the GIP/glucagon-only or amylin-class arguments turn out to have legs—and the DiMarchi/Tschöp paper from two weeks ago is one signal that they might—VK3019 is the hedge.

Third, the market is impatient. An 8.5% stock drop on a quarter that delivered enrolled trials, an IND filing, and a strategically positioned amylin program suggests investors wanted faster headline data, not pipeline depth. That tension—between the long horizons of obesity Phase 3 trials and the demand for quarterly progress—will be a recurring feature of how Viking trades over the next 18 months.

For the broader competitive picture across retatrutide, tirzepatide, semaglutide, and the rest of the obesity pipeline, our weight-loss compound articles walk through evidence tier, mechanism, and trial portfolio for every approved and late-stage candidate.

References

1. Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update. PRNewswire. April 29, 2026. PRNewswire
2. Viking Therapeutics Q1 2026 loss widens on R&D spend. Stock Titan. 2026.
3. Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735. PRNewswire.
4. Bays HE et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity. 2026.